1. Separation of bile acid isomer plays a pivotal role in bioequivalence evaluation of ursodeoxycholic acid.
- Author
-
Chang, Yanbo, Li, Xuejing, Jiang, Jinping, Gui, Lanlan, Wan, Linfei, Zhou, Xiangxiang, Liao, Linchuan, Li, Kexin, and Lan, Ke
- Subjects
- *
URSODEOXYCHOLIC acid , *LIQUID chromatography-mass spectrometry , *ELECTROSPRAY ionization mass spectrometry , *BILE acids , *ISOMERS , *AMMONIUM acetate , *MATRIX effect - Abstract
Based on our experiences in bile acid profiling, this work developed and validated a liquid chromatography electrospray ionization tandem mass spectrometry method to separate endogenous bile acid isomers and quantitatively determine ursodeoxycholic acid (UDCA), glycoursodeoxycholic acid (GUDCA) and tauroursodeoxycholic acid (TUDCA) in human plasma. The separation was performed on a CORTECS C18 column with the mobile phase consisting of 1.0 mM ammonium acetate and acetonitrile-methanol (80:20, v/v). UDCA, GUDCA and TUDCA were detected in the negative mode on a triple-quadrupole mass spectrometer at the ion transitions of m/z 391 > 391, m/z 448 > 74, m/z 498 > 80, respectively. Phosphate buffer was employed as the surrogate matrix to establish the isotope internal standard corrected calibration curves of analytes. The background-method with a linearity range of 10–200 ng/mL was partially validated to determine the endogenous levels of analytes in blank human plasma, which was incorporated into the validation of bioequivalence-method with a linearity range of 50–10000 ng/mL. The bioequivalence (BE)-method was fully validated with special focus on matrix effects, which have been critically evaluated using the precision and accuracy of quality control samples prepared from the blank human plasma of 12 individuals. It is disclosed for the first time that the BE results of UDCA formulation may yield false results when the method is insufficient to separate UDCA from isoursodeoxycholic acid, a microbial metabolite of both endogenous and exogenous UDCA. The present method has established a milestone for the evaluation of UDCA formulations and is expected to provide a valuable reference for the bioanalytical development of endogenous medicinal products. • A high-resolution LC-MS assay for plasma UDCA, GUDCA and TUDCA was validated. • The assay is specific and robust to separate analytes form their endogenous isomers. • Phosphate buffer was used as surrogate matrix with matrix effects critically evaluated. • Insufficient separation of UDCA and isoUDCA lead to false bioequivalence results. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF